Paloque, L., Coppée, R., Stokes, B. H., Gnädig, N. F., Niaré, K., Augereau, J.-M., Fidock, D. A., Clain, J., & Benoit-Vical, F. (2022). Mutation in the Plasmodium falciparum BTB/POZ Domain of K13 Protein Confers Artemisinin Resistance. Antimicrobial Agents and Chemotherapy, 66(1). https://doi.org/10.1128/aac.01320-21

Kanai, M., Yeo, T., Asua, V., Rosenthal, P. J., Fidock, D. A., & Mok, S. (2022). Comparative Analysis of Plasmodium falciparum Genotyping via SNP Detection, Microsatellite Profiling, and Whole-Genome Sequencing. Antimicrobial Agents and Chemotherapy, 66(1). https://doi.org/10.1128/aac.01163-21

McCarthy, J. S., Yalkinoglu, Ö., Odedra, A., Webster, R., Oeuvray, C., Tappert, A., Bezuidenhout, D., Giddins, M. J., Dhingra, S. K., Fidock, D. A., Marquart, L., Webb, L., Yin, X., Khandelwal, A., & Bagchus, W. M. (2021). Safety, pharmacokinetics, and antimalarial activity of the novel plasmodium eukaryotic translation elongation factor 2 inhibitor M5717: a first-in-human, randomised, placebo-controlled, double-blind, single ascending dose study and volunteer infection study. The Lancet Infectious Diseases, 21(12), 1713–1724. https://doi.org/10.1016/s1473-3099(21)00252-8

Shah, M. P., Hwang, J., Choi, L., Lindblade, K. A., Kachur, S. P., & Desai, M. (2021). Mass drug administration for malaria. Cochrane Database of Systematic Reviews, 2021(9). https://doi.org/10.1002/14651858.cd008846.pub3

Forte, B., Ottilie, S., Plater, A., Campo, B., Dechering, K. J., Gamo, F. J., Goldberg, D. E., Istvan, E. S., Lee, M., Lukens, A. K., McNamara, C. W., Niles, J. C., Okombo, J., Pasaje, C. F. A., Siegel, M. G., Wirth, D., Wyllie, S., Fidock, D. A., Baragaña, B., … Gilbert, I. H. (2021). Prioritization of Molecular Targets for Antimalarial Drug Discovery. ACS Infectious Diseases, 7(10), 2764–2776. https://doi.org/10.1021/acsinfecdis.1c00322